FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to embodiments of IgG-Fc polypeptides of domestic animals. Invention provides obtaining polypeptide IgG-Fc components having low binding affinity with C1q and CD16 and/or low antibody-dependent cell cytotoxicity (ADCC), as well as fused polypeptides based thereon with GLP-1 or glucagon, having increased half-life in blood serum.
EFFECT: invention can be used in veterinary science for treating diabetes, obesity and metabolic disease associated with diabetes or obesity.
61 cl, 7 dwg, 10 tbl, 17 ex
Title | Year | Author | Number |
---|---|---|---|
IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
ANTI-IL31 ANTIBODIES FOR VETERINARY USE | 2018 |
|
RU2795485C2 |
ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
HUMAN COAGULATION FACTOR FUSED PROTEIN FX (FIX), METHOD FOR PRODUCTION AND USE THEREOF | 2017 |
|
RU2736339C1 |
POLYVALENT AND POLYSPECIFIC GITR-BINDING FUSED PROTEINS | 2016 |
|
RU2753439C2 |
HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
FUSED SERPIN POLYPEPTIDES AND METHODS FOR USE THEREOF | 2019 |
|
RU2728861C1 |
BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF THEIR USE | 2019 |
|
RU2800779C2 |
Authors
Dates
2024-03-07—Published
2018-08-15—Filed